Recent Updates
Recently added Catalysts

CP-751, 871

Phase 2

Colorectal Neoplasm | Monoclonal antibody | Oncology |Pfizer, Inc.|Last Updated: May 20, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment168

FDA Designations

No designations recorded

Clinical trial landscape

CP-751, 871 · 1 trial · 1 indication

Phase 2 1
NCT00560560Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer TreatmentsColorectal Neoplasm
COMPLETED168 Analytics
PHASE2COMPLETED
Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
Colorectal Neoplasm
NCT00560560168
Unlock trial analytics

Study Endpoints

Primary Endpoints

Estimate of the 6 Month Survival Probability
Baseline up to Month 6

The 6 month survival probability was defined as the probability of survival at 6 months based on the Kaplan-Meier estimate. The time was from date of enrollment to date of death due to any cause. For participants who were last known to be alive, overall survival was censored at the last contact date.

Secondary Endpoints

Overall Survival
From date of enrollment until death or censorship, up to 33 months
Progression-Free Survival (PFS)
Baseline until tumor progression or censorship, up to 33 months. The frequency of tumor assessments was screening, every cycle, end of treatment (within 28 days of last dose of study drug), and follow-up.
Percentage of Participants With Objective Response
Baseline, every cycle (Day 15-21 or according to local standard), end of treatment (within 28 days of last dose of study drug) and follow-up (150 days after last dose of study drug), up to 33 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALSingle arm study

Interventions

NameTypeDescription
CP-751, 871BIOLOGICALHuman IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: * Patients who have stage IV colorectal cancer * Patients whose disease has worsened despite prior anti-cancer therapy * Patients who have satisfactory bonemarrow, kidney and liver function Exclusion Criteria: * Patients who are being simultaneously treated with another anti-c...

Countries:United StatesSpainUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about CP-751, 871

What is CP-751,871 used for?

CP-751,871 is an investigational monoclonal antibody being studied in oncology for several cancers, including prostate cancer, non-small-cell lung cancer, colorectal neoplasms, multiple myeloma, Ewing's sarcoma family of tumors, and advanced non-hematologic malignancies. It is being developed by Pfizer, Inc. (NYSE: PFE).

What does CP-751,871 target?

CP-751,871 targets the insulin-like growth factor 1 receptor (IGF-1R), as indicated by its study title 'Anti-IGF-IR CP-751,871'. By binding to this receptor, the antibody is designed to interfere with cancer cell growth signaling pathways.

Who makes CP-751,871?

CP-751,871 is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials of this investigational drug in multiple oncology indications.

What phase is CP-751,871 in?

CP-751,871 is in Phase 2 clinical development. It has completed three trials, including a Phase 2 study in prostate cancer and Phase 1 studies in other solid tumors. It is not FDA approved and remains investigational.

What clinical trials is CP-751,871 in?

CP-751,871 has completed three clinical trials: NCT00313781 (Phase 2, prostate cancer, 204 patients), NCT00474760 (Phase 1, Ewing's sarcoma, 65 patients), and NCT00603538 (Phase 1, non-small-cell lung cancer, 19 patients). All trials are completed with no active studies.

Is CP-751,871 the same as figitumumab?

CP-751,871 is also known as figitumumab, a name used in some clinical literature. This investigational monoclonal antibody targeting IGF-1R has been studied under both names in Pfizer's oncology trials.